CN104606406B - 一种外用预防变应性鼻炎的中药膏及其制备方法 - Google Patents
一种外用预防变应性鼻炎的中药膏及其制备方法 Download PDFInfo
- Publication number
- CN104606406B CN104606406B CN201510042713.9A CN201510042713A CN104606406B CN 104606406 B CN104606406 B CN 104606406B CN 201510042713 A CN201510042713 A CN 201510042713A CN 104606406 B CN104606406 B CN 104606406B
- Authority
- CN
- China
- Prior art keywords
- parts
- allergic rhinitis
- traditional chinese
- external application
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 32
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 32
- 239000002674 ointment Substances 0.000 title claims abstract description 31
- 230000002265 prevention Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 40
- 241000218394 Magnolia liliiflora Species 0.000 claims abstract description 20
- 241001116389 Aloe Species 0.000 claims abstract description 14
- 235000017965 Asarum canadense Nutrition 0.000 claims abstract description 14
- 241000928504 Centipeda minima Species 0.000 claims abstract description 14
- 235000000385 Costus speciosus Nutrition 0.000 claims abstract description 14
- 244000124853 Perilla frutescens Species 0.000 claims abstract description 14
- 240000003731 Piper cubeba Species 0.000 claims abstract description 14
- 235000002711 Piper cubeba Nutrition 0.000 claims abstract description 14
- 241000606265 Valeriana jatamansi Species 0.000 claims abstract description 14
- 235000014687 Zingiber zerumbet Nutrition 0.000 claims abstract description 14
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 14
- 240000000073 Achillea millefolium Species 0.000 claims abstract description 13
- 235000007754 Achillea millefolium Nutrition 0.000 claims abstract description 13
- 241000931705 Cicada Species 0.000 claims abstract description 13
- 244000246386 Mentha pulegium Species 0.000 claims abstract description 13
- 235000016257 Mentha pulegium Nutrition 0.000 claims abstract description 13
- 235000004357 Mentha x piperita Nutrition 0.000 claims abstract description 13
- 235000001050 hortel pimenta Nutrition 0.000 claims abstract description 13
- 239000000341 volatile oil Substances 0.000 claims description 32
- 239000006071 cream Substances 0.000 claims description 21
- 239000000284 extract Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000004677 Nylon Substances 0.000 claims description 7
- 239000004744 fabric Substances 0.000 claims description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229920001778 nylon Polymers 0.000 claims description 7
- 235000020737 peppermint extract Nutrition 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims 1
- 238000004821 distillation Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 210000000952 spleen Anatomy 0.000 abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 3
- 231100000956 nontoxicity Toxicity 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 48
- 239000000796 flavoring agent Substances 0.000 description 22
- 235000019634 flavors Nutrition 0.000 description 22
- 210000001331 nose Anatomy 0.000 description 22
- 230000006870 function Effects 0.000 description 17
- 238000000034 method Methods 0.000 description 14
- 230000010415 tropism Effects 0.000 description 13
- 230000003266 anti-allergic effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 10
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000002429 large intestine Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- 206010039083 rhinitis Diseases 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- 238000001467 acupuncture Methods 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000001256 steam distillation Methods 0.000 description 6
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 5
- 210000004709 eyebrow Anatomy 0.000 description 5
- 229940041616 menthol Drugs 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 210000003811 finger Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000003813 thumb Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 235000014676 Phragmites communis Nutrition 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 201000002266 mite infestation Diseases 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010002368 Anger Diseases 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 150000001545 azulenes Chemical class 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 2
- 229940116229 borneol Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 235000019994 cava Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 150000000193 1,8-cineol derivatives Chemical class 0.000 description 1
- 125000002006 1,8-cineol group Chemical group 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- GKQJMUAJFMIWIU-UHFFFAOYSA-N Asarumin A Natural products COC(=O)C(O)(C(C)C)C(C)OC(=O)C1=CC=CC=C1 GKQJMUAJFMIWIU-UHFFFAOYSA-N 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- 208000026344 Nasal disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 238000003457 Shi epoxidation reaction Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- GKQJMUAJFMIWIU-NHYWBVRUSA-N [(2s,3s)-3-hydroxy-3-methoxycarbonyl-4-methylpentan-2-yl] benzoate Chemical compound COC(=O)[C@](O)(C(C)C)[C@H](C)OC(=O)C1=CC=CC=C1 GKQJMUAJFMIWIU-NHYWBVRUSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000000537 nasal bone Anatomy 0.000 description 1
- 208000016366 nasal cavity polyp Diseases 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000006502 papoula Nutrition 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical group [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及医药领域,特别涉及一种外用预防变应性鼻炎的中药膏及其制备方法。该外用预防变应性鼻炎的中药膏原料包括芦荟、辛夷、薄荷、艾叶、甘草、鹅不食草、白苏叶、杜衡、陈皮、牡丹皮、蝉蜕、黄芩、荜澄茄、蓍草。本发明配合穴位按摩,能够未病先治、补益肺脾、祛风散邪、宣通鼻窍;内病外治,通过药物的透皮吸收发挥作用与刺激经络穴位对人体发挥调节的双重效应,具有无毒性、无痛苦、实施简单、疗效显著等优点,值得临床推广。
Description
(一)技术领域
本发明涉及医药领域,特别涉及一种外用预防变应性鼻炎的中药膏及其制备方法。
(二)背景技术
目前针对变应性鼻炎的研究大多集中在治疗方面,西医治疗变应性鼻炎以免疫疗法和药物治疗为主,免疫疗法疗程长,不易坚持;药物治疗虽然改善症状较快,但容易复发且毒副作用大。中医药治疗以口服、外用及针灸为主,口服及针灸因给患者带来一定的痛苦且疗程长,患者不易接受;外用药物以直接应用于鼻腔内为主,应用不当给鼻粘膜造成不可逆的损伤。对变应性鼻炎的预防也只是局限于尽量减少与过敏原的接触等,而面对环境污染的加剧,大气可吸入颗粒物所致变应性鼻炎逐年增加的现象,加强对变应性鼻炎预防的研究更显重要。
(三)发明内容
本发明为了弥补现有技术的不足,发明了一种无毒性、无痛苦、实施简单、疗效显著的外用预防变应性鼻炎的中药膏及其制备方法。
本发明是通过如下技术方案实现的:
一种外用预防变应性鼻炎的中药膏,其特征是:由以下重量份数的组分制成:芦荟10份-30份、辛夷20份-40份、薄荷5份-15份、艾叶5份-15份、甘草10份-30份、鹅不食草5份-15份、白苏叶5份-15份、杜衡5份-15份、陈皮5份-15份、牡丹皮5份-15份、蝉蜕5份-15份、黄芩5份-15份、荜澄茄5份-15份、蓍草5份-15份。
更优配方由以下重量份数的组分制成:芦荟20份、辛夷30份、薄荷10份、艾叶10份、甘草20份、鹅不食草10、白苏叶10份、杜衡10份、陈皮10份、牡丹皮10份、蝉蜕10份、黄芩10份、荜澄茄10份、蓍草10份。
外用预防变应性鼻炎的中药膏的制备方法,其特征在于:包括如下步骤:
(1)将上述芦荟用清水洗净,切碎,置于清洁消毒后的布袋中,压榨出汁液,并用80-100目的尼龙纱布过滤,得到芦荟胶;
(2)将上述辛夷、薄荷、艾叶分别浸泡5-10h,分别加入其质量的10-14倍水,通过水蒸气蒸馏法分别提取挥发油;
(3)将上述甘草、鹅不食草、白苏叶、杜衡、陈皮、牡丹皮、蝉蜕、黄芩、荜澄茄、蓍草清洗干净,然后在药锅中加入3倍重量份数的水煎2-5h,取上清液蒸发为稀膏状,得到稀膏;
(4)将上述芦荟胶,辛夷提取挥发油,薄荷提取挥发油,艾叶提取挥发油和稀膏三者均匀混合后,既得外用预防变应性鼻炎的中药膏。
本发明可以预防变应性鼻炎,同时可以配合穴位按摩协同治疗以预防变应性鼻炎,本发明中药膏还可以作为药物载体加入其他的药物成分以治疗相应的疾病。
以下是上述本发明的药物中各种原药材的功能和作用:
芦荟:性味:苦,寒;归经:归肝、大肠经;功能主治:泻下,清肝,杀虫;主治热结便秘,肝火头痛,目赤惊风,虫积腹痛,疥癣,痔痿;芦荟胶是从天然草本植物“芦荟”中萃取而成,质粘降泄,具有抗菌杀菌、免疫调节作用。
辛夷:性味:辛,温;归经:归肺、胃经;功能主治:散风寒,通鼻窍;主治风寒头痛,鼻塞,鼻渊,鼻流浊涕;现代研究证明:辛夷挥发油对慢反应物质、组胺、Ach所致的过敏性反应有明显的拮抗作用,抑制组胺引起的毛细血管通透性增高而产生抗过敏作用。
薄荷:性味:味辛,性凉;归经:归肺,肝经;功能主治:散风热,清头目,利咽喉,透疹,解郁。主风热表证,头痛目赤,咽喉肿痛,麻疹不透,陷疹瘙痒,肝郁胁痛。薄荷挥发油中主要成分为薄荷醇(menthol)又称薄荷脑,薄荷醇属于萜(烯)类渗透促进剂,其主要作用机理是破坏角质层中细胞的脂质屏障,增加药物从水溶性基质向角质层的分布和其作用于皮肤表皮引起超微结构的改变;薄荷醇能够优先的分配进入细胞间隙的角质层,然后可逆的分裂细胞间脂质,从而增加药物的透过,同时增加脂质双分子层的流动性,使得药物的渗透率提高,尤其在中药渗透促进剂中作用最强。
艾叶:性味:辛、苦,温;归经:归肝、脾、肾经;功能主治:温经止血,安胎,逐寒湿,理气血;主治吐衄,下血,崩漏,月经不调,痛经,带下,胎动不安,心腹冷痛,泄泻久痢,霍乱转筋,疮疡,疥癣;艾叶挥发油具有止咳、平喘、祛痰、消炎的作用,临床常用于治疗慢性支气管炎、肺气肿、支气管哮喘等疾病;挥发油的主要药效成分是1,8-桉叶素、樟脑、龙脑、甘菊环等;其中1,8-桉叶素具有止咳作用,甘菊环具有抗溃疡作用,樟脑具有杀菌、消炎作用,龙脑具有止痛、消肿作用。艾叶挥发油对免疫球蛋白E(IgE)介导的速发型变态反应有明显抑制作用。
甘草:性味:甘,平;归经:脾,胃,心,肺经;现代研究证明具有明显的抗过敏作用,甘草中的糖蛋白成分能抑制免疫球蛋白E(IgE)的产生;甘草甜素能抑制靶细胞脱颗粒和组织胺的释放;甘草根及糖甙有对抗乙酰胆碱和组织胺的作用,并能抑制抗体和免疫记忆细胞的产生,阻止巨噬细胞对抗原的处理。
鹅不食草:性味:辛,温;归经:归肺、肝经;功能主治:祛风通窍,解毒消肿;主治感冒,头痛,鼻渊,鼻息肉,咳嗽,哮喘,喉痹,耳聋,目赤翳膜,疟疾,痢疾,风湿痹病,跌打损伤,肿毒,疥癣;现代研究证明其具有明显的抗变态反应活性,鹅不食草的热水提取物经被动皮肤过敏试验表现出具显着的抗变态反应活性。
白苏叶:性味:辛,温;归经:归肺、脾经;功能主治:疏风宣肺,理气消食,解鱼蟹毒;主治感冒风寒,咳嗽气喘,脘腹胀闷,食积不化,吐泻,冷痢,中鱼蟹毒,男子阴肿;现代研究证明白苏叶的抗过敏物质在体外有直接抑制巨噬细胞产生TNF的能力,还能抑制免疫球蛋白E(IgE)产生。
杜衡:性味:辛,温,小毒;功能主治:祛风散寒,消痰行水,活血解毒;主治风寒感冒,痰饮喘咳,水肿,风寒湿痹,跌打损伤,头痛,齿痛,胃痛,痧气腹痛,瘰疬,肿毒,蛇咬伤;现代研究证明具有明显抗过敏作用,杜衡的醋酸乙酯提取物中的杜衡素A、B、C和亚油酸对大鼠被动皮肤过敏反应具有抑制作用。
陈皮:性味:辛、苦,温;归经:归脾、胃、肺经;功能主治:理气调中,降逆止呕,燥湿化痰;主治胸膈满闷,脘腹胀痛,不思饮食,呕吐,哕逆;咳嗽痰多;乳痈初起;现代药理研究具有明显抗过敏作用。
牡丹皮:性味:辛苦,凉,微寒;归经:心,肝,肾,肺经;功能主治:清热,活血散瘀;主温热病热入血分,发斑,吐衄,热泪盈眶病菌后期热伏阴分发热,阴虚骨蒸潮热,血滞经闭,痛经,痈肿疮毒,跌扑伤痛,风湿热痹。现代药理研究具有明显抗变态反应,对第Ⅰ、Ⅲ、Ⅳ型变态反应有显著的抑制功效。
蝉蜕:性味:甘,寒;归经:归肺、肝经;散风除热,利咽,透疹,退翳,解痉。现代药理研究具有明显抗过敏作用。
黄芩:性味:苦,寒;归经:归肺、心、肝、胆、大肠经;功能主治:清热泻火,燥湿解毒,止血,安胎;主治肺热咳嗽,热病高热神昏,肝火头痛,目赤肿痛,湿热黄疸,泻痢,热淋,吐衄,崩漏,胎热不安,痈肿疔疮;现代研究证明:有抗变态反应作用,黄芩甙和黄芩素可抑制被动皮肤过敏反应,并有抗组胺、抗胆碱及罂粟样作用。
荜澄茄:性味:辛,温;归经:归胃、脾、肾、膀胱经;功能主治:温中散寒,行气止痛,暖肾;主治胃寒呕逆,脘腹胀满冷痛,肠鸣泄泻,寒疝腹痛,寒湿小便淋沥浑浊;现代研究证明:荜澄茄挥发油具有明显抗过敏作用。
蓍草:性味:辛、苦,微寒,有毒;功能主治:祛风止痛,活血,解毒;主治感冒发热,头风痛,牙痛,风湿痹痛,经闭腹痛,腹部痞块,跌打损伤,破伤出血,痈肿疮毒,毒蛇咬伤;现代研究证明有明显抗过敏作用。
本发明药膏可以配合穴位按摩预防变应性鼻炎:
本发明所选用穴位为:印堂、迎香、鼻通(上迎香)、蝶腭穴、下关、合谷、足三里。中医学认为鼻为肺之外腑,与肺气相连,位居阳中之阳,是血脉多聚之处,又是清阳交会之处,本病发病与肺、脾、肾功能失调有关,以肺阴虚或肺气虚为主,故取穴以鼻旁局部取穴及与肺经相表里的大肠经穴为主。
印堂为经外奇穴,但位于督脉的循行线上,位于两眉之间,督脉沿额正中下行至鼻柱,至鼻尖端,为通利鼻窍之要穴,且督脉为诸阳之会,故刺激印堂穴可鼓舞阳气,透诸经而除百病,故其具有温经散寒,宣通经络,扶阳固表,防病保健的功效。
迎香穴为手阳明大肠经穴,位于鼻窍之旁,可治疗一切鼻部疾患,足阳明起于鼻,手足阳明两脉相接于本穴。大肠与肺相表里,肺卫不固等肺经疾病选取此穴,具有散风祛邪、宣肺通鼻窍之功。现代研究证实,刺激迎香穴能抑制组胺形成和释放,并能抑制和降低毛细血管壁及细胞膜的通透性,减少炎症渗出。
鼻通穴又名上迎香,为经外奇穴,位于鼻骨下凹陷中,鼻唇沟上端尽处,定位紧连鼻旁,所以对鼻塞、多涕等鼻病症状有效,取之能使局部经气畅通,升提阳气。
蝶腭穴(蝶腭神经节)是近年来被发现的治疗常年性变应性鼻炎非常有效的刺激点,此穴从现代解剖学的角度来看,不仅集中了源于三叉神经的感觉支,还有来自翼神经的交感和副交感支等,刺激此点通过刺激鼻腔内的植物神经可以使其恢复平衡而达到治疗目的。
下关为肺经相表里的大肠经穴,有宣肺通鼻之功,为治疗鼻病要穴。
合谷为四总穴之一,“面口合谷收”,是治疗颜面五官疾患之要穴,且为手阳明大肠经之原穴,肺与大肠相表里,手阳明大肠经“络肺下膈属大肠”“最后抵于鼻旁”,可解表祛邪,治疗外感鼻疾等与肺相关的病证。
足三里为足阳明胃经的合穴,足阳明胃经起于鼻旁,为经脉所过的远端取穴,针刺该穴“培土生金”,补益肺脾肾之气,以达益气固表、扶正祛邪之效。
以上诸穴合用能激发机体的自身调节作用,使脏腑功能达到协调,起到补益肺脾的功效,又能祛风散邪、宣通鼻窍。
本发明中药膏涂抹配合穴位按摩治疗原则为“未病先治、补益肺脾、祛风散邪、宣通鼻窍”;作用机制是:内病外治,通过药物的透皮吸收发挥作用与刺激经络穴位对人体发挥调节的双重效应。
使用方法:于早、晚患者清洗手、面后,取适量鼻炎膏均匀涂抹鼻、及面颊部,用双手食指或拇指分别按摩印堂、通鼻及双侧迎香、下关、蝶腭穴,正反各20次,然后由拇指及食指上下交替捏鼻双侧鼻翼20次。当患者感觉有乏力、畏冷等不适症状或者外界环境条件变化时,适当增加次数,同时对双侧合谷穴及足三里穴进行涂抹并按摩正反各20次。
本发明的有益效果为:
1、所用原材料为天然中药:味辛升散、味甘温补、味苦清热解毒;性温温阳通窍、温经散寒,少量寒性药物以防辛温太过,诸药合用共起补益肺脾、祛风散邪、宣通鼻窍的功效。归肺、脾、胃、肾经等,符合中医循经入药的原理。
2、鼻炎膏涂抹配合穴位按摩是在传统的针灸医学基础上应用中药作用于俞穴,通过药物的气味、归经,益气去风、温阳通窍达到祛除病因,纠正阴阳偏盛偏衰,恢复脏腑功能协调的作用,另外,药物对腧穴的刺激,促使经络发挥整体调节作用从而调和阴阳、扶正祛邪、行气通络、芳香通窍,使药物直接到达病灶,起到活血化瘀、抗菌消炎、消肿、改善局部血液循环作用,进而促进局部新陈代谢及炎性渗出物吸收,减轻炎症刺达到治疗疾病的目的。清代名医徐灵胎谓:“用膏药贴之,闭塞其气,使药性从毛孔而入其腠理,通经贯络,或提而出之,或攻而散之,较之服药尤有力,此至妙之法”,很好地诠释了药物涂抹配合穴位按摩的作用机理。
3、本研究中药鼻炎膏涂抹配合穴位按摩正是取圣人治“未病”之道作为对变应性鼻炎患儿的预防性治疗,具有无毒性、无痛苦、实施简单、疗效显著等优点。本研发明 中药鼻炎膏无色、微清香,涂抹于皮肤微凉的舒服感,亦可作为护肤品长期应用。本发明的穴位按摩方法简单,经辅导可以自行操作,年幼患者也可以在辅导下自己操作或者乐意接受操作。
(四)具体实施方式
实施例1
本发明外用预防变应性鼻炎的中药膏制备方法包括以下步骤:
(1)、将上述芦荟10g用清水洗净,切碎,置于清洁消毒后的布袋中,压榨出汁液,并用80-100目的尼龙纱布过滤,得到芦荟胶;
(2)、将上述辛夷20g、薄荷5g、艾叶5g分别浸泡5-10h,分别加入其质量的10-14倍水,通过水蒸气蒸馏法分别提取挥发油;
(3)将上述甘草10g、鹅不食草5g、白苏叶5g、杜衡5g、陈皮5g、牡丹皮5g、蝉蜕5g、黄芩5g、荜澄茄5g、蓍草5g清洗干净,然后在药锅中加入3倍重量份数的水煎2-5h,取上清液蒸发为稀膏状,得到稀膏;
(4)将上述芦荟胶,辛夷提取挥发油,薄荷提取挥发油,艾叶提取挥发油和稀膏三者均匀混合后,既得外用预防变应性鼻炎的中药膏。
使用方法:于早、晚患者清洗手、面后,取适量鼻炎膏均匀涂抹鼻、及面颊部,用双手食指或拇指分别按摩印堂、通鼻及双侧迎香、下关、蝶腭穴,正反各20次,然后由拇指及食指上下交替捏鼻双侧鼻翼20次。当患者感觉有乏力、畏冷等不适症状或者外界环境条件变化时,适当增加次数,同时对双侧合谷穴及足三里穴进行涂抹并按摩正反各20次。
实施例2
本发明外用预防变应性鼻炎的中药膏制备方法包括以下步骤:
(1)、将上述芦荟30g用清水洗净,切碎,置于清洁消毒后的布袋中,压榨出汁液,并用80-100目的尼龙纱布过滤,得到芦荟胶;
(2)、将上述辛夷40g、薄荷15g、艾叶15g分别浸泡5-10h,分别加入其质量的10-14倍水,通过水蒸气蒸馏法分别提取挥发油;
(3)将上述甘草30g、鹅不食草15g、白苏叶15g、杜衡15g、陈皮15g、牡丹皮15g、蝉蜕15g、黄芩15g、荜澄茄15g、蓍草15g清洗干净,然后在药锅中加入3倍重量份数的水煎2-5h,取上清液蒸发为稀膏状,得到稀膏;
(4)将上述芦荟胶,辛夷提取挥发油,薄荷提取挥发油,艾叶提取挥发油和稀膏三者均匀混合后,既得外用预防变应性鼻炎的中药膏。
使用方法:同实施例1。
实施例3
本发明外用预防变应性鼻炎的中药膏制备方法包括以下步骤:
(1)、将上述芦荟20g用清水洗净,切碎,置于清洁消毒后的布袋中,压榨出汁液,并用80-100目的尼龙纱布过滤,得到芦荟胶;
(2)、将上述辛夷30g、薄荷10g、艾叶10g分别浸泡5-10h,分别加入其质量的10-14倍水,通过水蒸气蒸馏法分别提取挥发油;
(3)将上述甘草20g、鹅不食草10g、白苏叶10g、杜衡10g、陈皮10g、牡丹皮10g、蝉蜕10g、黄芩10g、荜澄茄10g、蓍草10g清洗干净,然后在药锅中加入3倍重量份数的水煎2-5h,取上清液蒸发为稀膏状,得到稀膏;
(4)将上述芦荟胶,辛夷提取挥发油,薄荷提取挥发油,艾叶提取挥发油和稀膏三者均匀混合后,既得外用预防变应性鼻炎的中药膏。
使用方法:同实施例1。
实施例4
本发明外用预防变应性鼻炎的中药膏制备方法包括以下步骤:
(1)、将上述芦荟22g用清水洗净,切碎,置于清洁消毒后的布袋中,压榨出汁液,并用80-100目的尼龙纱布过滤,得到芦荟胶;
(2)、将上述辛夷35g、薄荷12g、艾叶11g分别浸泡5-10h,分别加入其质量的10-14倍水,通过水蒸气蒸馏法分别提取挥发油;
(3)将上述甘草18g、鹅不食草12g、白苏叶11g、杜衡12g、陈皮12g、牡丹皮12g、蝉蜕12g、黄芩12g、荜澄茄12g、蓍草12g清洗干净,然后在药锅中加入3倍重量份数的水煎2-5h,取上清液蒸发为稀膏状,得到稀膏;
(4)将上述芦荟胶,辛夷提取挥发油,薄荷提取挥发油,艾叶提取挥发油和稀膏三者均匀混合后,既得外用预防变应性鼻炎的中药膏。
使用方法:同实施例1。
实施例5
本发明外用预防变应性鼻炎的中药膏制备方法包括以下步骤:
(1)、将上述芦荟15g用清水洗净,切碎,置于清洁消毒后的布袋中,压榨出汁液,并用80-100目的尼龙纱布过滤,得到芦荟胶;
(2)、将上述辛夷22g、薄荷8g、艾叶8g分别浸泡5-10h,分别加入其质量的10-14倍水,通过水蒸气蒸馏法分别提取挥发油;
(3)将上述甘草12g、鹅不食草9g、白苏叶8g、杜衡9g、陈皮9g、牡丹皮9g、蝉蜕8g、黄芩9g、荜澄茄9g、蓍草9g清洗干净,然后在药锅中加入3倍重量份数的水煎2-5h,取上清液蒸发为稀膏状,得到稀膏;
(4)将上述芦荟胶,辛夷提取挥发油,薄荷提取挥发油,艾叶提取挥发油和稀膏三者均匀混合后,既得外用预防变应性鼻炎的中药膏。
使用方法:同实施例1。
临床观察
1、临床资料
100例儿童均为2012年10月-2013年10月我科门诊就诊患者,按《变应性鼻炎诊断标准及疗效评定标准》(1997年修订)确诊为变应性鼻炎,经系统治疗,临床症状体征显著明显缓解,血清IgE及IL-4水平明显下降,临床治疗显效的患者,年龄在5-14岁之间,同意签署知情同意书者,随机分为治疗组组及对照组,各组分别为50例,两组在年龄、性别、IgE及IL-4下降水平、临床症状、体征控制效果及体质状况等方面无统计学差异。
2方法
2.1治疗组:变应性鼻炎患儿临床症状及体征明显好转后坚持用鼻炎膏涂抹配合穴位按摩治疗、同时注意饮食调节及加强体育锻炼,疗程一年。
2.2对照组:用粉尘螨滴剂(畅迪)浙江我武生物科技有限公司生产[国药准字]S20060012,[规格]2ml,2000μg;舌下含服,按递增法,按说明书依次使用1-4号滴剂,坚持体育锻炼及注意饮食调节,疗程一年。
3、观测指标
3.1疗效性检查指标:血清IgE及IL-4的检测,临床症状:喷嚏、流涕、鼻塞、鼻痒,体征:鼻黏膜色泽和水肿程度、鼻甲情况等。
3.2安全性检查指标:血、尿、便常规,肝功能(ALT)/肾功能(BUN、Gr),心电图检查。
3.3观察方法:每例患儿均建立随访病例表,分别于治疗前、治疗中发病时、治疗结束时各记录一次。
4、结果
4.1治疗结束后两组间发病情况比较,见表1:
表1治疗结束后两组间发病情况比较
经卡方检验,P<0.05,两组之间有统计学的差异。
4.2两组治疗前后血清IgE及IL-4的组内、组间比较,见表2:
表2 两组治疗前后血清IgE(IU/ml)及IL-4(ng/ml-2)的组内、组间比较
1)治疗前两组组间血清IgE比较,P>0.05,可认为治疗前两组组间血清IgE值近似相等;
2)治疗后两组组间血清IgE比较,P<0.05,治疗后治疗组IgE值较对照组IgE值明显下降;
3)治疗前后组内血清IgE比较,P<0.05,治疗组经过治疗后IgE值较治疗前明显下降,对照组经过治疗后IgE值较治疗前略有下降;
4)治疗前两组组间血清IL-4比较,P>0.05,可认为治疗前两组组间血清IL-4值近似相等;
5)治疗后两组组间血清IL-4比较,P<0.05,治疗后治疗组IL-4值较对照组IL-4值明显下降;
6)治疗前后组内血清IL-4比较,P<0.05,治疗组经过治疗后IL-4值较治疗前明显下降,对照组经过治疗后IL-4值较治疗前略有下降;
7)其中,每组治疗人数n=50。
4.3两组治疗后再发病患儿病情及比较见表3,同样治疗情况下治疗组疗效明显好于对照组。
表3 两组治疗后再发病患儿病情及疗效比较
4.4安全性评价:本次研究中,两种疗法在治疗后均无不良反应
及不良事件发生,相关生化检查(肝肾功能)、心电图、血尿粪常规在治疗前后均无异常。
Claims (2)
1.一种外用预防变应性鼻炎的中药膏,其特征是:由以下重量份数的组分制成:芦荟10份-30份、辛夷20份-40份、薄荷5份-15份、艾叶5份-15份、甘草10份-30份、鹅不食草5份-15份、白苏叶5份-15份、杜衡5份-15份、陈皮5份-15份、牡丹皮5份-15份、蝉蜕5份-15份、黄芩5份-15份、荜澄茄5份-15份、蓍草5份-15份;
包括如下步骤:
(1)将上述芦荟用清水洗净,切碎,置于清洁消毒后的布袋中,压榨出汁液,并用80-100目的尼龙纱布过滤,得到芦荟胶;
(2)将上述辛夷、薄荷、艾叶分别浸泡5-10h,分别加入其质量的10-14倍水,通过水蒸气蒸馏法分别提取挥发油;
(3)将上述甘草、鹅不食草、白苏叶、杜衡、陈皮、牡丹皮、蝉蜕、黄芩、荜澄茄、蓍草清洗干净,然后在药锅中加入3倍重量份数的水煎2-5h,取上清液蒸发为稀膏状,得到稀膏;
(4)将上述芦荟胶,辛夷提取挥发油,薄荷提取挥发油,艾叶提取挥发油和稀膏三者均匀混合后,既得外用预防变应性鼻炎的中药膏。
2.根据权利要求1所述的外用预防变应性鼻炎的中药膏,其特征是:由以下重量份数的组分制成:芦荟20份、辛夷30份、薄荷10份、艾叶10份、甘草20份、鹅不食草10、白苏叶10份、杜衡10份、陈皮10份、牡丹皮10份、蝉蜕10份、黄芩10份、荜澄茄10份、蓍草10份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510042713.9A CN104606406B (zh) | 2015-01-28 | 2015-01-28 | 一种外用预防变应性鼻炎的中药膏及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510042713.9A CN104606406B (zh) | 2015-01-28 | 2015-01-28 | 一种外用预防变应性鼻炎的中药膏及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104606406A CN104606406A (zh) | 2015-05-13 |
CN104606406B true CN104606406B (zh) | 2018-11-02 |
Family
ID=53141226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510042713.9A Active CN104606406B (zh) | 2015-01-28 | 2015-01-28 | 一种外用预防变应性鼻炎的中药膏及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104606406B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105687557A (zh) * | 2016-01-26 | 2016-06-22 | 刘汉业 | 一种本草鼻炎膏及其制作方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1965985A (zh) * | 2006-11-20 | 2007-05-23 | 李淑洁 | 一种内服治疗小儿过敏性鼻炎的中药合剂及制备方法 |
CN101530473A (zh) * | 2009-04-21 | 2009-09-16 | 沈阳双鼎制药有限公司 | 鼻通喷雾剂及其制备方法 |
CN101804097A (zh) * | 2010-03-16 | 2010-08-18 | 扈福证 | 石芩通窍软膏及其制备方法 |
-
2015
- 2015-01-28 CN CN201510042713.9A patent/CN104606406B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1965985A (zh) * | 2006-11-20 | 2007-05-23 | 李淑洁 | 一种内服治疗小儿过敏性鼻炎的中药合剂及制备方法 |
CN101530473A (zh) * | 2009-04-21 | 2009-09-16 | 沈阳双鼎制药有限公司 | 鼻通喷雾剂及其制备方法 |
CN101804097A (zh) * | 2010-03-16 | 2010-08-18 | 扈福证 | 石芩通窍软膏及其制备方法 |
Non-Patent Citations (2)
Title |
---|
"中医外治法治疗变应性鼻炎的近况";王军;《甘肃中医》;20100915;第23卷(第9期);第76-78页 * |
"中医药治疗变应性鼻炎辨证用药特点及分析";程坚等;《中华中医药杂志》;20120630;第27卷(第7期);第1947-1950页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104606406A (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768541A (zh) | 一种治疗慢性支气管炎的药物 | |
CN103520461B (zh) | 一种用于治疗过敏性鼻炎的药物 | |
CN102631530B (zh) | 一种治疗瘙痒型红丝疔的中药洗剂制备方法 | |
CN110721303A (zh) | 一种治疗过敏性鼻炎的中药组合物及其应用 | |
CN104606406B (zh) | 一种外用预防变应性鼻炎的中药膏及其制备方法 | |
CN104784346A (zh) | 一种治疗瘙痒症的中药洗剂制备方法 | |
CN104524174A (zh) | 一种治疗风湿痹痛的中药组合物及其制备方法 | |
CN102266435A (zh) | 一种专治牛皮癣的中药 | |
CN102380081B (zh) | 一种治疗麻木型褥疮的中药洗剂制备方法 | |
CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
CN110496200A (zh) | 一种治疗肺结核的中药组合物及其制备方法和应用 | |
CN103520591B (zh) | 用于慢性荨麻疹的中药 | |
CN103263645B (zh) | 一种治疗胃炎、胃溃疡的药物 | |
CN103751624B (zh) | 一种治疗中风后肢体麻木的药物及制备方法 | |
CN102579777A (zh) | 一种治疗搔痒型臁疮的中药洗剂制备方法 | |
CN104645224A (zh) | 一种治疗肋软骨炎的中药制剂 | |
CN105561007A (zh) | 一种用于治疗小儿流行性感冒的中药制剂及制备方法 | |
CN104399053A (zh) | 一种用于治疗精神分裂症的药物及制备方法 | |
CN104784567B (zh) | 一种治疗泌尿系感染的药物组合物 | |
CN103893509B (zh) | 一种治疗过敏性鼻炎的药物及制备方法 | |
CN105169301A (zh) | 一种治疗痰湿内阻型月经不调的中药组合物 | |
CN104771638A (zh) | 用于治疗视神经萎缩的中药组合物 | |
CN104383338A (zh) | 一种治疗慢性肾绞痛的中药制剂 | |
CN104274594B (zh) | 一种治疗三叉神经痛的中药制剂 | |
CN103432409B (zh) | 一种治疗嗜食烤肉型腋下急性化脓性淋巴结炎的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |